Related Experiment Video

Updated: May 15, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD

Henrik Watz1, Daniel Bock, Michael Meyer

  • 1Pulmonary Research Institute at Hospital Grosshansdorf, Center for Pneumology and Thoracic Surgery, Airway Research Center North, German Center for Lung Research, D-22927 Grosshansdorf, Germany.

Pulmonary Pharmacology & Therapeutics
|December 22, 2012
PubMed

Insights

Inhaled Bimosiamose is a safe and well-tolerated treatment for chronic obstructive pulmonary disease (COPD) patients. This pan-selectin antagonist effectively reduces airway inflammation, showing promise for COPD management.

Area of Science:

  • Pulmonology and Respiratory Medicine
  • Pharmacology and Therapeutics
  • Immunology and Inflammation

Background:

  • Selectins are key cell adhesion molecules mediating leukocyte extravasation to inflammatory sites.
  • Chronic obstructive pulmonary disease (COPD) is characterized by chronic airway inflammation.
  • Targeting selectins offers a potential therapeutic strategy for managing COPD exacerbations and progression.

Purpose of the Study:

  • To evaluate the safety and efficacy of inhaled Bimosiamose, a pan-selectin antagonist, in patients with COPD.
  • To assess the impact of Bimosiamose on inflammatory markers and lung function in COPD.
  • To determine the tolerability of inhaled Bimosiamose as an adjunct therapy in COPD.

Main Methods:

  • A randomized, double-blind, placebo-controlled, multi-center crossover trial involving 77 COPD patients.
  • Patients inhaled Bimosiamose (10 mg) or placebo twice daily for 28 days, alongside standard bronchodilator therapy.
  • Efficacy assessed via inflammatory parameters (interleukin-8, cell counts) in induced sputum and lung function tests.

Main Results:

  • Bimosiamose was safe and well-tolerated, with a balanced adverse event profile compared to placebo.
  • Significant reduction in interleukin-8 concentration (p=0.008) and macrophage count (p=0.012) observed with Bimosiamose.
  • Neutrophil count showed a non-significant decrease; lung function parameters demonstrated minor numeric increases.

Conclusions:

  • Inhaled Bimosiamose is a safe and well-tolerated treatment for COPD patients.
  • Bimosiamose effectively attenuates airway inflammation by reducing key inflammatory mediators and cell counts.
  • The findings support further investigation of inhaled Bimosiamose as a therapeutic option for COPD.

More Related Videos

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization02:46

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...